Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18379149 | 1.00 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2D6KDM4ECHRM2 | |
| SCHEMBL10241157 | 0.90 | SMN1; SMN2 (0.38) | CYP3A4CYP1A2CYP2D6KDM4ECHRM2 | |
| SCHEMBL17553814 | 0.82 | INPP5A (0.38) | CYP3A4CYP1A2CYP2D6INPP5A | |
| SCHEMBL3429840 | 0.80 | CHRNB2 (0.35) | INPP5ABCHE | |
| SCHEMBL3429844 | 0.80 | CHRNB2 (0.37) | CYP1A2KDM4EINPP5ABCHEALDH1A1 | |
| SCHEMBL10241703 | 0.79 | SMN1; SMN2 (0.44) | KDM4ECHRM3INPP5ABCHE | |
| SCHEMBL18379267 | 0.77 | SMN1; SMN2 (0.49) | CYP2D6CHRM2CHRM1CHRM3INPP5A | |
| SCHEMBL14565210 | 0.77 | SMN1; SMN2 (0.49) | CYP2D6CHRM2CHRM1CHRM3INPP5A | |
| SCHEMBL25153263 | 0.75 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2D6KDM4ECHRM2 | |
| SCHEMBL6923031 | 0.74 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2D6KDM4ECHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CYP3A4 1291/4885CYP1A2 1595/4885CYP2D6 1699/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | CYP3A4 1682/4885CYP1A2 507/4885CYP2D6 1361/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | CYP3A4 1682/4885CYP1A2 507/4885CYP2D6 1361/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | CYP3A4 1682/4885CYP1A2 507/4885CYP2D6 1361/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | CYP3A4 1682/4885CYP1A2 507/4885CYP2D6 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.